Ingenol mebutate 0.015% gel is safe for short-term treatment of actinic keratoses on the face in solid organ transplant recipients.

Immunosuppressed solid organ transplant recipients (SOTR) have a high burden of AK, but have been excluded from clinical trials of ingenol mebutate 0.015% gel. This leaves dermatologists and transplant teams to extrapolate safety data from immunocompetent patients or from two case reports of use in SOTR. This single-arm, open-label investigator-initiated study investigated the safety and tolerability of topical ingenol mebutate 0.015% gel in SOTR.